Table 3A. Cox proportional-hazards analyses of OS and RFS (A) for patients with proximal colon cancer, according to APC mutation status and microsatellite instability (discovery cohort); and (B) for patients with proximal colon cancer, according to APC gene signature and microsatellite instability (validation cohort, GSE39582 (Marisa et al, 2013)); (A) Discovery cohort.

	Overall survival		Recurrence-free survival
	HR (95% CI)	P	HR (95% CI)	P
MSI vs APC-mt/MSS	0.88 (0.49–1.57)	0.656	0.59 (0.27–1.29)	0.185
APC-wt/MSS/ vs MSI	2.05 (1.11–3.77)	0.022*	3.34 (1.45–7.68)	0.005*
APC-wt/MSS vs APC-mt/MSS	1.79 (1.11–2.88)	0.016*	1.97 (1.06–3.63)	0.031*
Age (Decades)	1.41 (1.09–1.82)	0.009*	1.08 (0.81–1.45)	0.588
Gender (Female vs Male)	0.92 (0.60–1.42)	0.718	0.93 (0.54–1.60)	0.794
Stage II vs I	1.85 (0.43–8.06)	0.412	1.19 (0.25–5.68)	0.824
Stage III vs I	5.04 (1.16–21.82)	0.030*	5.84 (1.26–27.04)	0.024*
Stage IV vs I	19.21 (4.25–86.76)	<0.001*
Chemotherapy (Yes vs No)	1.03 (0.60–1.76)	0.919	0.91 (0.44–1.88)	0.807
Events/N	91/282		55/182

Abbreviations: CI=confidence interval; HR=hazard ratio; MSI=microsatellite instability; MSS=microsatellite stable; OS=overall survival; RFS=recurrence-free survival.

Analyses are adjusted for gender, age at diagnosis, tumour stage and treatment. To facilitate comparisons between APC wild-type/mutated tumour groups, hazard ratios are presented for all pairwise combinations of reference states.